Your browser doesn't support javascript.
loading
Management guideline for the off-label use of medicine in China (2021).
Zuo, Wei; Sun, Yajia; Liu, Rongji; Du, Liping; Yang, Nan; Sun, Wenjuan; Wang, Ping; Tang, Xiaowan; Liu, Yunlan; Ma, Yuanyuan; Meng, Min; Lei, Ruobing; Yan, Xuelian; Peng, Hua; Chang, Qing; Pan, Hui; Zhang, Bo; Chen, Yaolong; Zhang, Shuyang.
Afiliação
  • Zuo W; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Sun Y; School of Public Health, Lanzhou University, Lanzhou, China.
  • Liu R; Institute of Health Data Science, Lanzhou University, Lanzhou, China.
  • Du L; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Yang N; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Sun W; Institute of Health Data Science, Lanzhou University, Lanzhou, China.
  • Wang P; Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
  • Tang X; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Liu Y; Institute of Health Data Science, Lanzhou University, Lanzhou, China.
  • Ma Y; Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
  • Meng M; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Lei R; School of Public Health, Lanzhou University, Lanzhou, China.
  • Yan X; Institute of Health Data Science, Lanzhou University, Lanzhou, China.
  • Peng H; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chang Q; Chevidence Laboratory Child & Adolescent Health, Department of Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Chongqing, China.
  • Pan H; National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Cho
  • Zhang B; Chongqing Key Laboratory of Pediatrics, Chongqing, China.
  • Chen Y; Gansu Provincial Hospital, Lanzhou, China.
  • Zhang S; Chevidence Laboratory Child & Adolescent Health, Department of Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Chongqing, China.
Expert Rev Clin Pharmacol ; 15(10): 1253-1268, 2022 Oct.
Article em En | MEDLINE | ID: mdl-36047057
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Uso Off-Label Tipo de estudo: Guideline / Qualitative_research / Systematic_reviews Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Expert Rev Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Uso Off-Label Tipo de estudo: Guideline / Qualitative_research / Systematic_reviews Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Expert Rev Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido